Extra-Nuclear Signaling of Progesterone Receptor to Breast Cancer Cell Movement and Invasion through the Actin Cytoskeleton by Fu, Xiao-Dong et al.
Extra-Nuclear Signaling of Progesterone Receptor to
Breast Cancer Cell Movement and Invasion through the
Actin Cytoskeleton
Xiao-Dong Fu
1,2, Maria S. Giretti
1, Chiara Baldacci
1, Silvia Garibaldi
1, Marina Flamini
1, Angel Matias
Sanchez
1, Angiolo Gadducci
1, Andrea R. Genazzani
1, Tommaso Simoncini
1*
1Molecular and Cellular Gynecological Endocrinology Laboratory (MCGEL), Department of Reproductive Medicine and Child Development, University of Pisa, Pisa, Italy,
2Department of Physiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China
Abstract
Progesterone plays a role in breast cancer development and progression but the effects on breast cancer cell movement or
invasion have not been fully explored. In this study, we investigate the actions of natural progesterone and of the synthetic
progestin medroxyprogesterone acetate (MPA) on actin cytoskeleton remodeling and on breast cancer cell movement and
invasion. In particular, we characterize the nongenomic signaling cascades implicated in these actions. T47-D breast cancer
cells display enhanced horizontal migration and invasion of three-dimensional matrices in the presence of both progestins.
Exposure to the hormones triggers a rapid remodeling of the actin cytoskeleton and the formation of membrane ruffles
required for cell movement, which are dependent on the rapid phosphorylation of the actin-regulatory protein moesin. The
extra-cellular small GTPase RhoA/Rho-associated kinase (ROCK-2) cascade plays central role in progesterone- and MPA-
induced moesin activation, cell migration and invasion. In the presence of progesterone, progesterone receptor A (PRA)
interacts with the G protein Ga13, while MPA drives PR to interact with tyrosine kinase c-Src and to activate
phosphatidylinositol-3 kinase, leading to the activation of RhoA/ROCK-2. In conclusion, our findings manifest that
progesterone and MPA promote breast cancer cell movement via rapid actin cytoskeleton remodeling, which are mediated
by moesin activation. These events are triggered by RhoA/ROCK-2 cascade through partially differing pathways by the two
compounds. These results provide original mechanistic explanations for the effects of progestins on breast cancer
progression and highlight potential targets to treat endocrine-sensitive breast cancers.
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Introduction
Estrogen is regarded as a carcinogenic factor in the breast [1]
and have recently found that estrogen may also alter breast cancer
progression by promoting tumour cells motility [2]. However, the
role of progesterone receptor (PR) signaling in the development
and progression of breast cancer is poorly characterized
notwithstanding its relevance in the clinical setting [1]. To this
extent, the Multiethnic Cohort and Women’s Health Initiative
trials show an increased incidence of breast cancer in postmen-
opausal women receiving combined hormone therapy with
estrogens and progestogens as compared to the women receiving
estrogens alone, suggesting that progestins may play a deleterious
role on breast cancer [3–5].
Local breast cancer spread and its later diffusion to the lymph
nodes or to distant sites are the main cause of morbidity and death
[6]. The generation of cancer cell movement in the surrounding
environment is the first step in these processes and involves a
complex set of cellular actions. A critical step is represented by the
remodeling of the actin cytoskeleton toward the cell membrane,
which allows the formation of bridges between the backbone of the
cell and the extracellular matrix mediated by anchorage proteins.
The ensuing contractions of the cytoskeleton generate cell
movement [7]. Actin remodeling (particularly the loss of stress
fibres) is also involved in cancer transformation and metastasis [8].
Moesin, a member of the ezrin/radixin/moesin (ERM) family,
is an actin-binding protein that plays an important role in cell
motility by linking the actin cytoskeleton to a variety of
membrane-anchoring proteins [9,10]. In quiescent conditions
moesin exists in an auto-inhibited conformation and phosphory-
lation of Thr
558 within the C-terminal actin binding domain by the
Rho-associated kinase (ROCK), results in a conformational
change and in the association with the scaffold protein, ezrin/
radixin/moesin-binding protein 50 (EBP50) on moesin’s NH2-
terminal end and with F-actin on moesin’s COOH-terminal end
to mediate the linkage of microfilaments to membranes in cell
surface microvilli [11].
We recently showed that estrogen controls actin remodeling in
endothelial cells via the activation of moesin [12]. This ensues
through a rapid, extra-nuclear signaling cascade originated by the
interaction of ERa with the G protein Ga13. This process leads to
the recruitment of RhoA and of the Rho associated kinase, ROCK-
2 and to moesin activation. This pathway leads to the formation of
membrane ruffles and pseudopodia which interact with the
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migration [12]. Moreover, the activation of this pathway mediates
estrogen-induced migration and invasion of breast cancer cells [2].
The pharmacological properties of progestins are not equal
[13,14]. These pharmacological discrepancies may account for the
diverse impact of progestins on breast cancer development and
progression. For instance, the E3N-EPIC cohort study show that
continuous-combined HRT with different progestins is associated
with the different relative risk and subtype of breast cancer in
postmenopausal women [15,16]. Hence it would be clinically
important to be able to differentiate the effects on breast cells of
the different progestins used for HRT.
The sex steroid progesterone and the various synthetic
progestins act in human cells through progesterone receptor
(PR) A and PRB [17]. Beyond being transcription factors actively
involved in the regulation of gene expression, PRs also act via
rapid, extra-nuclear, signaling cascades, such as via the phospha-
tidylinositol 3-kinase (PI3K)/Akt or the c-Src/extracellular signal-
regulated kinases 1/2 (ERK1/2) pathways, playing an important
role in breast cancer development [18,19]. However, little is
known on the functional relevance of PR signaling for breast
cancer progression.
In this manuscript we investigate the regulatory actions of PR
on breast cancer cell migration and invasion and we characterize
the extra-nuclear signaling events recruited by PR.
Results
Progesterone and MPA drive breast cancer cell migration
and invasion
First we observed the actions of progesterone and MPA on T47-
D breast cancer cell migration and invasion. Before treatment,
T47-D breast cancer cells were pretreated with cytosine b-D-
arabinofuranoside hydrochloride (Ara-C - 10 mM) to prevent cell
division. Activation of progesterone receptor (PR) with either
natural progesterone (P, 100 nM) or the synthetic progestin
medroxyprogesterone acetate (MPA, 100 nM) resulted in en-
hanced migration vs. vehicle-treated cells (Fig. 1A). In the inserts
Figure 1. PR activation increases T47-D cell migration and invasion. (A) Cells were treated with progesterone or MPA (both 100 nM) for 48 h
and cell migration was assayed. T47-D cells were scraped out of the cell culture dish and the extent of migration of the remaining cells was assayed in
the presence of Ara-C (see text). Cell migration distances were measured and values are presented as % of control. *=P,0.01 vs. control. The
experiments were performed in triplicates and data representing the migration distance of cells from the starting line are expressed as mean6SD.
The arrows indicate the direction of migration. The upper black lines indicate the starting line and the lower black lines indicate the mean migration
distance. (B) Cells were treated with progesterone or MPA (both 100 nM) for 48 h. Cell invasion was assayed using invasion chambers. Invading cells
were counted in three different central fields of triplicate membranes. The experiments were performed in triplicates. Invasion indexes and
representative images are shown. *=P,0.01 vs. control.
doi:10.1371/journal.pone.0002790.g001
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invasion of the matrix by cancer cells (Fig. 1B). The number of
cells that invaded the matrix in the presence of MPA was higher
than with P (Fig. 1B).
Rapid activation of PR is linked to breast cancer cell
cytoskeletal and cell membrane rearrangement
Actin fibers in ER
+/PR
+ T47-D breast cancer at baseline were
arranged longitudinally in the cytoplasm and the cell membrane
was regular. Activation of PR with P (100 nM) or MPA (100 nM)
resulted in a rapid shift of the actin fibers toward the edge of the
membrane. This was associated with a significant increase of the
thickness of the cell membrane and of its fluorescence intensity,
quantified by analyzing the pixel intensity in a box including the
cell membrane as well as the adjacent intra- and extra-cellular
space (Fig. 2A, 2B and Table 1). In parallel, cell membrane ruffles
and pseudopodia were formed at sites enriched in actin (Fig. 2A).
These effects were maximal between 10 and 15 minutes and
began to revert after 30 minutes (Fig. 2A, 2B and Table 1). These
processes were prevented by the pure PR antagonist ORG 31710
(Fig. 2A, 2B and Table 1).
When the globular/fibrillar (G/F) actin ratio was assayed in
T47-D cells, similar changes were observed. At baseline, actin
predominantly existed as monomers (G-actin), while after
recruitment of PR with P or MPA for 15 min, a rapid shift
toward F-actin was found that was prevented by ORG 31710
(Figure 2C), indicating that PR activation is linked to rapid actin
polymerization. The amount of total actin (G-actin+F-actin) was
comparable in all conditions (Figure 2C).
Recruitment of PR leads to activation of the actin-
regulatory protein, moesin
Moesin rapidly increased in T47-D cells exposed to P (100 nM)
or MPA (100 nM) between 2 (mean increases of moesin
phosphorylation: P 73%, MPA 102%) and 15 minutes (mean
increases of moesin phosphorylation: P 183%, MPA 268%) and
then declined after 30 minutes, time-consistently with the kinetics
of actin rearrangement (Fig. 3A–B). Moesin activation was related
to concentration of the PR agonists (Fig. 3C–D). Supporting the
requirement of PR, the same PR agonists did not alter moesin
phosphorylation in MDA-MB-231 breast cancer cells, that do not
express PR (Fig. 3E–F). In addition, moesin phosphorylation was
slightly increased by the addition of E2 (1 nM) to each progestin
compared to the progestins alone, although this was not
statistically significant (Fig. 3G).
To establish the requirement of moesin for the PR-induced
actin reorganization in T47-D cells we silenced moesin expression
by transfecting specific antisense phosphorotioate oligonucleotides
(PONs). After exposure to antisense moesin PONs for 48 h,
moesin protein expression (Fig. 3H) and cell immunostaining
(Fig. 3I) in T47-D cells were greatly reduced. Moesin-silenced
T47-D cells did not respond with actin or cell membrane
remodeling when PR was recruited by either P or MPA (Fig. 3I).
As control, non-transfected T47-D cells or cells receiving sense
Figure 2. PR activation induces a rapid rearrangement of the actin cytoskeleton in T47-D cells. (A) T47-D cells were treated with P or
MPA (both 100 nM) for 10, 15 or 30 minutes, in the presence or absence of the pure PR antagonist ORG 31710 (1 mM). Immunofluorescent analysis of
Texas Red-phalloidin (in red) reveals the spatial modifications of actin fibres through the time-course and the formation of specialized cell membrane
structures. Green, yellow and light blue arrows indicate lamellipodia, pseudopodia and ruffles, respectively. Nuclei are counterstained in blue.
Rectangles indicate the area sampled in the corresponding upper graph. In the graph, the longitudinal axis displays the gray level and the horizontal
axis shows the pixels. Light yellow, light red and light blue areas indicate the parts of the graph indicating the extracellular, plasma membrane and
cytoplasmic areas. (B) Analytic results obtained by using Leica QWin image analysis and processing software showing the mean thickness of the cell
membrane after treatment with P or MPA (both 100 nM). The results are derived from the sampling of five areas of the cell membrane of thirty
different random cells. The areas of minimum and maximum cell membrane thickness were always included. The results are the mean6SD of the
measurements. (C) shows the amount of filamentous actin (F-actin, F) versus free globular-actin (G-actin, G) content in T47-D cells after treatment
with P or MPA (both 100 nM) for 15 min, in the presence or absence of PR antagonist ORG 31710 (1 mM). Positive (Pos) and negative (Neg) controls
were set by adding F-actin enhancing solution (phalloidin, 1 mM) or F-actin depolymerization solution (10 mM cytochalasin-D) to the lysates,
respectively. All the experiments were repeated three times with consistent results, and a representative result is shown. *=P,0.05 vs control.
doi:10.1371/journal.pone.0002790.g002
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membrane reorganization in response to PR recruitment (Fig. 3I).
Characterization if the initiation of PR signaling to
moesin
The rapid time lapse of moesin activation and deactivation
suggests that PR signals to this protein via ‘‘nongenomic’’ or
‘‘extra-nuclear’’ cascades [20]. Indeed, activation of PR with
either P or MPA still resulted in moesin activation even if RNA or
protein synthesis was blocked in T47-D cells with actinomycin D
(Act D - 10 mM) or cycloheximide (CHX - 200 mM) (Fig. 4A).
Blockade of PR with ORG 31710 completely abolished both P-
and MPA-dependent moesin activation, confirming that PR is the
steroid receptor used by these agonists to signal to moesin (Fig. 4B–
C). Interference with the ERK1/2 cascade with PD98059 did not
alter the activation of moesin (Fig. 4B–C). Interestingly, inhibition
of G proteins with pertussis toxin (PTX) prevented the activation
of moesin by P but not by MPA, while inhibition of
phosphatidylinositol-3OH kinase (PI3K) with wortmannin exclu-
sively blocked the action of MPA but not that of P (Fig. 4B–C).
These findings indicate that PR signals to moesin via a G protein-
dependent pathway when bound by P, and via a PI3K-dependent
pathway in the presence of MPA.
PR ligands exert their actions through the two PR isoforms,
PRA and PRB, which are both expressed by the T47-D cells used
in this study (Fig. 4D). However, in contrast to P, MPA also binds
the glucocorticoid receptor (GR), that mediates some of its actions
[21,22]. This different receptor binding pattern explains some of
the biological differences of the two compounds [21,22]. However,
phosphorylation of moesin in the presence of MPA was equally
prevented by the pure PR antagonist ORG 31710 as well as by the
mixed PR/GR antagonist RU486, suggesting that GR does not
play a role in MPA signaling to moesin (Fig. 4E). In agreement,
moesin was not phosphorylated in the presence of hydrocortisone
(50 nM) (Fig. 4E).
PR activation of ERK1/2 and PI3K in breast cancer cells is
associated with cell proliferation and inhibition of apoptosis
[18,23]. Consistent with these reports, exposure of T47-D cells to
P resulted in a time-dependent activation of ERK1/2 and of the
PI3K effector, Akt (Fig. 5A–B).
However, recruitment of PR with either P or MPA in T47-D
cells after silencing of ERK 1/2 with siRNAs (Fig. 5C) still resulted
in activation of moesin (Fig. 5D), confirming that signaling of PR
to the ERK1/2 mitogen-activated protein kinase (MAPK) cascade
is not implicated in moesin activation.
Transfection of T47-D cells with a dominant negative form of
the regulatory subunit of PI3K, p85a (Dp85a), resulted in the
impairment of the PR-dependent moesin activation induced by
MPA, but had no inhibitory effect on P (Fig. 5E), implying that
PI3K only plays a role in PR signaling to moesin induced by MPA.
As control, the transfection of a wild-type p85a construct (WT
p85) did not alter moesin activation induced by P nor MPA
(Fig. 5E).
The G protein Ga13 is an established controller of the
cytoskeleton and of cell movement [24]. Co-immunoprecipitation
studies showed that, in the presence of progesterone, PRA started
to interact with Ga13. The PRA/Ga13 interaction was ligand-
dependent, being prevented by ORG 31710, but not by PTX
(Fig. 6A). In addition, the PRA/Ga13 interaction was ligand-
specific, as it was not triggered by MPA (Fig. 6A). Differently from
PRA, a basal interaction between PRB and Ga13 was found,
which was not altered by the addition of either P or MPA (Fig. 6A).
As G proteins reside on the cell-membrane and sub-sets of PRs
have also been identified at this level [25,26], we used the
membrane-impermeable bovine serum albumin-progesterone
conjugate (P-BSA - 100 nM) to explore if binding of PR at the
cell membrane may be involved in moesin activation. Indeed,
exposure of T47-D cells to P-BSA resulted in rapid activation of
moesin (Fig. 6B).
PR interacts with the tyrosine kinase c-Src [27], and this process
is involved in the activation of PI3K [28]. We thus explored the
role of c-Src for the PR-dependent activation of moesin induced
by MPA. Administration of MPA to T47-D cells lead to activation
of the PI3K target Akt and of moesin, both of which were
prevented by the Src kinase inhibitor, PP2 (Fig. 6C–D). Activation
of Akt and moesin were associated with a ligand-induced
interaction of both PRA and PRB with c-Src (Fig. 6E–F).
Silencing of c-Src with specific siRNAs (Fig. 6G) impaired the
activation of moesin by MPA (Fig 6H). In contrast, P was still able
to trigger moesin phosphorylation in c-Src-silenced cells (Fig. 6H),
reinforcing the hypothesis that PR signaling to moesin is ligand-
specific, and that the interaction with c-Src and the subsequent
recruitment of the PI3K/Akt pathway are absolutely required
when PR is engaged by MPA, but not in the presence of P.
Table 1. The table displays the mean thickness of the cell membrane, the mean actin intensity of the membrane and the
cytoplasm, as well as the ratio of the intensities of membrane/cytoplasm in T47-D cells treated with progesterone and MPA (both
100 nM) for different times, in the presence or absence of PR antagonist ORG 31710 (1 mM).
Mean membrane
thickness (pixel6SD)
Mean membrane intensity
(mean gray level6SD)
Mean cytosol intensity
(mean gray level6SD)
Membrane/cytosol
intensity ratio
09 28.465.2 60.367.8 58.666.6 1.04
109 P 52.868.3* 98.4610.2* 60.367.2 1.63*
MPA 66.269.4* 97.568.6* 64.568.4 1.61*
159 P 68.369.6* 104.6611.5* 62.468.3 1.74*
MPA 70.5610.3 * 106.8610.6* 56.469.1 1.86*
309 P 30.664.7 70.468.1 61.6 67.2 1.13
MPA 27.365.2 60.569.4 58.364.8 1.03
159+ORG P 27.565.6 58.266.9 60.467.5 0.98
MPA 30.664.4 64.3 67.2 56.165.5 1.27
Analytic results were obtained by using Leica QWin image analysis and processing software.
doi:10.1371/journal.pone.0002790.t001
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PLoS ONE | www.plosone.org 4 July 2008 | Volume 3 | Issue 7 | e2790Figure 3. PR activation turns into moesin activation. (A), (B) (C) and (D) show the time- and dose-dependent moesin activation in T47-D breast
cancer cells after recruitment of PR with P or MPA. Total cell amount of wild-type (Moesin) or Thr
558-phosphorylated moesin (P-Moesin) are shown
with western blot. *=P,0.05 vs control. (E) and (F) show that in MDA-MB-231 cells (that do not express PR), progesterone and MPA have no effect on
moesin activation. (G) shows that moesin activation induced by progestins alone or in combination with 17b-estradiol (E2). *=P,0.05 vs control. (H)
Moesin expression detected by western blot in T47-D cells transfected with moesin antisense PON for 48 h. (I) Actin remodeling after PR activation
with P or MPA for 15 min in T47-D cells after transfection with moesin antisense phosphorotioate oligonucleotides (PON) (antisense - 2 mM) or sense
PON (sense - 2 mM) for 48 h. Cells were stained with an Ab vs. moesin (FITC; green staining) as well as with Texas Red-phalloidin (in red). Nuclei are
counterstained in blue. All the experiments were repeated three times with consistent results, and a representative result is shown.
doi:10.1371/journal.pone.0002790.g003
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transfectedfull-lengthhumanPRAorPRBinER
2/PR
2MDA-MB-
231 breast cancer cells and studied the interaction with Ga13 or c-Src
and the activation of moesin. In MDA-MB-231 cells transfected with
the vector plasmid pcDNA3.1+, baseline or ligand-associated
interaction of PR with Ga13 or c-Src was negligible and no moesin
activation was observed (Fig. 6I). In MDA-MB-231 cells transfected
with PRA, P (but not MPA) enhanced the interaction of PRA with
Ga13 (Fig. 6I). In the same cells enhanced interaction of PRA with c-
Src was found in the presence of both P and MPA (Fig. 6I). In this
experimental condition, exposure to P as well as to MPA was
associated with increased moesin phosphorylation (Fig. 6I).
When MDA-MB-231 cells were transfected with PRB, a visible
co-interaction of this receptor with Ga13 was seen, which was not
altered by the presence of the ligands (Fig. 6I). Interaction of PRB
with c-Src was instead dependent on the presence of either P or
MPA (Fig. 6I). However, in these cells, only exposure to MPA
resulted in activation of moesin.
Overall, these results indicate that signaling to moesin in T47-D
cells is initiated through a PRA/Ga13 interaction in the presence
Figure 4. Extra-nuclear signaling of PR to moesin in T47-D cells. (A) T47-D cells were treated with progesterone or MPA (both 100 nM) for
15 min, in the presence or absence of Act D (10 mM) or CHX (200 mM). Moesin and phosphorylated moesin are shown. *=P,0.05 vs control. (B) and
(C) Cells were exposed to 100 nM progesterone or MPA for 15 min, in the presence or absence of the pure PR antagonist ORG 31710 (ORG - 1 mM), of
the MEK inhibitor PD98059 (PD - 5 mM), of the PI3K inhibitor wortmannin (WM - 30 nM) or of the G protein inhibitor, PTX (100 ng/mL). Cell contents
of wild-type or phosphorylated moesin are shown. (D) The expression of PRA and PRB in T47-D cell lysates is shown (M - marker proteins). (E) Cells
were exposed to 100 nM MPA or 50 nM hydrocortisone (Hydr) for 15 min, in the presence or absence of ORG 31710 (ORG - 1 mM) or of the combined
GR/PR antagonist, RU486 (RU - 1 mM), moesin and phosphorylated moesin are assayed with western analysis. The experiments were performed in
triplicates and representative images are shown.
doi:10.1371/journal.pone.0002790.g004
Figure 5. Extra-nuclear signaling of PR to moesin in T47-D cells: ERK1/2 and PI3K. (A) shows wild-type (ERK1/ERK2) or phosphorylated ERK
1/2 (P-ERK1/ERK2) during exposure to progesterone (100 nM). (B) Shows wild-type (Akt) and phosphorylated Akt (P-Akt) in the presence of 100 nM P.
(C) T47-D cells were transfected with scrambled siRNA or ERK1/2 targeted siRNAs for 48 h. After that level of ERK1/2 protein expression was detected
by western blot as indicated. (D) Cells were exposed to 100 nM P or MPA for 15 min after transfection with 100 nM targeted siRNA for ERK1/2 or
scrambled siRNA for 48 h. Cell contents of wild-type or phosphorylated moesin are shown. (E) Cells were exposed to 100 nM progesterone or MPA
for 15 min after transfection with constitutively active p85a (WT p85a) or dominant-negative p85a (Dp85a) for 48 h. Cell contents of p85a, wild-type
or phosphorylated moesin are shown. The experiments were performed in triplicates and representative images are shown.
doi:10.1371/journal.pone.0002790.g005
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recruitment of c-Src when MPA is present.
Later intracellular events linking activation of PR to
moesin: role of RhoA
The small GTPase RhoA mediates the signaling of a variety of
receptors to ERM proteins, including that of sex steroid receptors
[12]. Indeed, PR activation in T47-D cells with P or MPA increased
the amount of active, GTP-bound RhoA (Fig. 7A–B). In agreement
with the previous results, the PR-dependent recruitment of RhoA was
mediated by G proteins in the presence of P (Fig. 7A), while it
involved PI3K, and not G proteins, in the presence of MPA (Fig. 7B).
Supporting the role of Ga13 and RhoA in the signaling of PR,
moesin phosphorylation was ligand-independently induced by
transient transfection of Ga13 (Ga13 Q226L) or RhoA (RhoA
G14V) constitutively active constructs (Fig. 7C–D). In parallel,
transfection of a dominant negative RhoA (RhoA T19N) construct
resulted in a significant reduction of P- and MPA-induced moesin
phosphorylation (Fig. 7C–D). In line with the previous results, a
dominant negative Ga13 construct (Ga13 Q226L/D294N) de-
creased the amount of moesin phosphorylation induced by P but
not by MPA (Fig. 7C–D).
Later intracellular events linking activation of PR to
moesin: role of the Rho-associated kinase, ROCK-2
Blockade of ROCK-2 with the specific inhibitor Y-27632
prevented the PR-dependent moesin activation induced by P or
MPA (Fig. 8A–B). In addition, silencing of ROCK-2 with siRNAs
(Fig. 8C) prevented the PR-dependent moesin activation induced
by both P and MPA (Fig. 8D).
In the presence of progesterone, ROCK-2 was functionally
activated, as shown by enhanced Thr-phosphorylation of the bait
protein myelin basic protein (MBP) by ROCK-2 immunoprecipitates
(IPs) (Fig. 8E). ROCK-2 activation by P was prevented by the PR
antagonist ORG 31710 and by the G protein inhibitor, PTX
(Fig. 8E). Recruitment of PR by MPA also lead to ROCK-2
activation (Fig. 8F). ORG 31710 and the PI3K inhibitor wortmannin
inhibited this action of MPA, while PTX was ineffective (Fig. 8F).
Intracellular events linking activation of PR to cell
migration and invasion
We finally explored the signaling mechanisms implicated in cell
migration and invasion. P and MPA-enhanced cell migration was
inhibited by blocking PR with the pure PR antagonist ORG
31710 or ROCK with the specific inhibitor Y-27632 (Fig. 9A–B).
Inhibition of G proteins resulted in a near-complete blockade of
cell migration in the presence of either P or MPA (Fig. 9A–B),
consistent with a broader role of G proteins for cell movement,
that likely overrides the PR-to-ROCK cascade. Inhibition of PI3K
or of MAPK decreased both P- and MPA-promoted cell migration
to some extent (Fig. 9A–B). However, a statistically significant
reduction of cell migration was found only for the addition of
PD98059 to P treatment (Fig. 9A) and for the addition of
wortmannin to MPA treatment (Fig. 9B).
Figure 6. Extra-nuclear signaling of PR to moesin in T47-D cells: Ga13 and c-Src. (A) T47-D cells were treated for 15 minutes with P or MPA
(both 100 nM), in the presence or absence of ORG 31710 (ORG - 1 mM) or of PTX (100 ng/mL). Protein extracts were immunoprecipitated with an Ab
vs.G a13 and the IPs were assayed for co-immunoprecipitation of PRs. The cell extract (30 mg) was used as input and normal rabbit IgG was used as
the control antibody. (B) T47-D cells were exposed to 100 nM P-BSA (membrane-impermeable) for 15 min, in the presence or absence of ORG 31710
(ORG - 1 mM). Moesin and phosphorylated moesin are shown. (C) and (D) T47-D cells were treated with 100 nM MPA for 15 min, with or without the
Src kinase inhibitor, PP2 (10 mM) and wild-type or active Akt or moesin are shown. (E) and (F) T47-D cells were treated for 15 minutes with 100 nM
MPA, in the presence or absence of ORG 31710 (ORG - 1 mM). Protein extracts were immunoprecipitated with an Ab vs. PR (E) or c-Src (F) and the IPs
were assayed for co-immunoprecipitation of PR or c-Src as indicated. Cell extract (30 mg) was used as input. Normal rabbit IgG and normal mouse IgG
were used as the control antibodies in (E) and (F), respectively. (G) T47-D cells were transfected with scrambled siRNA or c-Src targeted siRNAs for
48 h. c-Src protein expression was detected by western blot as indicated. (H) T47-D cells were exposed to 100 nM P or MPA for 15 min after
transfection with c-Src siRNA or non-specific control siRNAs for 48 h. Total moesin or P-moesin cell amounts are shown. (I) PR-negative MDA-MB-231
cells were transiently transfected with empty pcDNA3.1+ plasmid (vector) or plasmids encoding full length of human PRA or PRB for 48 h, then cells
were exposed to 100 nM P or MPA for 15 min. Protein extracts were immunoprecipitated with an Ab vs. PR, and the IPs were assayed for co-
immunoprecipitation of Ga13 or c-Src as indicated. Total moesin and phosphorylated moesin were also analyzed using western blot. The experiments
were performed in triplicates and representative images are shown.
doi:10.1371/journal.pone.0002790.g006
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(Fig. 10A–B). The invasive behavior induced by P or MPA was
prevented by blocking PR, G proteins or ROCK-2 (Fig. 10A–B).
Lesser inhibitory effects were found in when the MAPK inhibitor,
PD98059 and of the PI3K inhibitor, wortmannin were added to
either P or MPA (Fig. 10A–B). Silencing of moesin with antisense
oligonucleotides (PON) fully prevented the effects of P and MPA
on cell migration and invasion (Fig. 9A–B, 10C), indicating the
pivitol role of moesin in these processes.
Estrogen promotes T47-D cell migration and invasion [2].
However, in the presence of 17b-estradiol (E2 - 1 nM), a slight but
non-significant additive effects was found during co-treatment with
P or MPA (Fig. 9A–B, 10A–B).
Discussion
Progesterone receptor is a fundamental orchestrator of breast
development and function [29], but is also implicated in breast
cancer development and progression, although its role in these
processes is still to be fully established [1]. Nonetheless, recent
evidence from clinical trials [4,30,31] suggests that exposure to
progesterone may a key factor for breast cancer.
Cancer cells spread locally and metastasize to distant organs
and these processes represent the chief cause of morbidity and
death [6]. Endocrine therapy using the progesterone receptor (PR)
antagonist RU486 prevents the development of mammary tumors
and induces the regression of lymph node and lung metastases in
mouse breast cancer models [32,33], supporting a role for PR in
these processes. In addition, PR agonists enhance the invasiveness
of breast cancer cells by increasing tissue factor or vascular
endothelial growth factor expression [34,35]. However, definitive
mechanistic explanations of the effects of PR on breast cancer cell
movement or invasion are not available.
Cell movement is a complex and highly integrated process. The
formation of a cortical actin complex at specialized membrane
structures, such as pseudopodia, lamellipodia and membrane ruffles
[36] bridges the cytoskeleton to the extracellular matrix. The actin-
binding protein moesin plays a central role in these processes [36,37].
Our previous findings show indicate that sex steroid receptors,
such as the estrogen receptor alpha, control moesin activity in
vascular cells [12] as well as in breast cancer cells [2]. In this
paper, we discover that PR signals to moesin in breast cancer cells
and this leads to rapid actin emodeling that supports horizontal
cell movement and invasion of three-dimensional matrices.
Estrogen slightly potentiates both progestins-enhanced cell migra-
tion and invasion Moesin is required for these tasks, as its silencing
results in reduced migration in the presence of progestins. These
findings are consistent with previous reports of effects of
progesterone on the formation of adhesion structures and on
cytoskeletal modifications in other breast cancer cell lines [38].
In the presence of progesterone, PRA interacts with the G
protein Ga13, therefore recruiting the RhoA/ROCK-2 cascade.
This results in moesin phosphorylation and in the morphological
changes in the cell. PRB also interacts with Ga13, however, this
interaction is not dependent on the presence of a ligand, nor it
recruits the Ga13/RhoA/ROCK-2 cascade.
The finding of the interaction of PRA and Ga13 is consistent
with previous reports of PR signaling through Gai and Gbc
[25,39,40]. Ga13 belongs to the G12 family that is critical for cell
movement and plays an important role in metastasis [24,41].
Figure 7. Extra-nuclear signaling of PR to moesin in T47-D cells: RhoA. (A) and (B) RhoA activity was assayed in cells treated with
progesterone or MPA (both 100 nM) for 15 min in the presence or absence of the pure PR antagonist ORG 31710 (ORG - 1 mM), of the PI3K inhibitor
wortmannin (WM - 30 nM), or of the G protein inhibitor, PTX (100 ng/mL). Active, GTP-bound RhoA was immunoprecipitated with Rhoteckin and
subsequently assayed with western analysis with an anti-RhoA Ab (lower boxes). The upper boxes show the total RhoA content in the input.
*=P,0.05 vs control, #=P,0.05 vs corresponding progestin. (C) and (D) T47-D cells were either mock-transfected or exposed to constitutively
active or dominant-negative RhoA (RhoA CA or RhoA DN) and Ga13 (Ga13 CA or Ga13 DN). Cells were then treated with progesterone or MPA (both
100 nM) for 15 min and wild type and P-moesin were analyzed. The experiments were performed in triplicates and representative images are shown.
doi:10.1371/journal.pone.0002790.g007
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increases cell invasion [42]. Our finding of the recruitment of
Ga13 by PRA thus provides a mechanistic explanation for the
progesterone-dependent breast cancer cell migration and invasion.
Recent work indicates the existence of membrane-localized
progesterone receptors [25,26]. As Ga13 is a cell membrane
protein, the finding that moesin phosphorylation can be induced
by a membrane-impermeable form of progesterone might be
Figure 8. Extra-nuclear signaling of PR to moesin in T47-D cells: ROCK-2. (A) and (B) T47-D cells were exposed for 15 min to progesterone or
MPA (both 100 nM) in the presence or absence of the ROCK-2 inhibitor, Y-27632 (Y - 10 mM) and moesin and phosphorylated moesin were assayed
with western analysis. *=P,0.05 vs control, #=P,0.05 vs corresponding progestin. (C) T47-D cells were transfected with scrambled siRNA or ROCK-
2 target siRNA for 48 h. ROCK-2 protein expression was detected by western blot. (D) Cells were exposed to 100 nM progesterone or MPA for 15 min
after transfection with 100 nM target siRNA for ROCK-2 or scrambled siRNA for 48 h. Cell contents of wild-type or phosphorylated moesin are shown.
(E) and (F) Cells were treated with progesterone or MPA (both 100 nM) for 15 min in the presence or absence of ORG 31710 (ORG - 1 mM), of
wortmannin (WM - 30 nM), of PTX (100 ng/mL) or of Y-27632 (Y - 10 mM). ROCK-2 was immunoprecipitated with a specific Ab and the IPs were used
to phosphorylate the bait protein, myelin basic protein (MBP). ROCK-2 kinase activity is shown as the amount of phosphorylated MBP (P-MBP).
*=P,0.05 vs control, #=P,0.05 vs corresponding progestin. The experiments were performed in triplicates and representative images are shown.
doi:10.1371/journal.pone.0002790.g008
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this is just suggestive and not conclusive. The identification of the
cellular site of PR/Ga13 interaction is therefore not solved and will
be the aim of future studies.
In normal mammary epithelial cells PR isoforms are co-
expressed equivalently. However, PR isoform predominance,
especially PRA predominance or an increased PRA/PRB ratio,
is found in a high proportion of breast cancers and correlates to
invasive behaviour [43,44]. Moreover, an increased PRA/PRB
ratio in breast cancer cells has been shown to induce changes in
cell morphology and the loss of cell adhesion in response to
progesterone receptor agonists, along with a membrane-to-
cytoplasm redistribution of the ERM protein, ezrin [45].
Increasing PRA levels in breast cancer cells is also associated with
altered expression of genes associated with regulation of cell shape
and adhesion [46]. More recently PRB (but not PRA) has been
shown to localize to the cytoplasm in response to progesterone and
thus to interact with c-Src. This leads to the activation of MAPK
and to subsequent up-regulation of cyclin D1 in breast cancer cells
[19]. To this extent, our finding of a divergent ability of PRA and
PRB to recruit the RhoA/ROCK-2 cascade stands in favour of a
different role of the two receptor isoforms during cell migration
and invasion.
PR-dependent recruitment of the MAPK and PI3K/Akt
pathways in the presence of natural progesterone does not seem
to be involved in moesin activation, but the inhibition of these two
pathways decreases cell migration and invasion in T47-D cells
exposed to progesterone. This implies that moesin is not the
exclusive tool mediating cell migration and invasion in the
presence of this PR agonist, which is not surprising. On the other
hand, PRA does not interact with Ga13 when bound by the
synthetic progestin, MPA, indicating a high degree of specificity of
this signaling event. Indeed, when MPA hits PRA or PRB, the
Src/PI3K/Akt pathway is rapidly recruited. This ultimately leads
to the activation of RhoA and ROCK-2 and, finally, of moesin. It
is possible that when engaged by MPA, PRs may be driven to form
a functional signaling module with Src and PI3K, where activated
PI3K would lead to recruitment of RhoA, as shown in other cells
[47]. In analogy, ER, Src and PI3K are reportedly organized into
a similar complex to mediate rapid signaling of estrogens in
endothelial cells [48].
While PI3K is critical for moesin activation by MPA, G proteins
and MAPK are still relevant for MPA-induced cell migration. A
similar result is found for breast cancer invasion of three-
dimensional matrices, where the inhibition of G proteins, ROCK
and MAPK all result in a significant decrease of progesterone-
induced cell invasion, notwithstanding the fact that MAPK are not
required for moesin activation by progesterone. These apparent
discrepancies are likely due to the complexity of the processes of
cell movement and invasion, that are controlled by multiple
internal and external signals [49].
Some of the present results point out that PR signals differently
when engaged by different agonists, such as P or MPA, and this
maybe responsible for their discrepant actions on some specific
endpoints, such as their different impacts on breast cancer subtype
[16]. The basis for this phenomenon is not currently understood.
Progestins act differentially in part due to the ability to engage
other steroid receptors [50]. MPA is able to bind the glucocor-
ticoid receptor (GR) and this explains some effects of this progestin
in endothelial cells [21]. However, GR is not responsible for the
MPA-dependent activation of moesin, possibly indicating that
conformational differences in PR might explain the differential
recruitment of signaling pathways in the presence of the two
ligands.
In conclusion, we show that PR is implicated in breast cancer
cell migration and invasion. Recruitment of PR by P or MPA leads
Figure 9. Intracellular signaling mechanisms involved in PR-enhanced T47-D cell migration. (A) and (B) Cells were treated with
progesterone or MPA (both 100 nM) for 48 h, in the presence or absence of ORG 31710 (ORG - 1 mM), of PD98059 (PD - 5 mM), of wortmannin (WM -
30 nM), of PTX (100 ng/mL), of Y-27632 (Y - 10 mM) or of 17b - estradiol (E2 - 1 nM). Other cells were transfected with moesin antisense
phosphorotioate oligonucleotides (PON) (antisense - 2 mM) or sense PON (sense - 2 mM). Cell migration distances were measured and values are
presented as % of control. *=P,0.01 vs. control; **=P,0.05 vs. progesterone or MPA. The experiments were performed in triplicates and data
representing the migration distance of cells from the starting line are expressed as mean6SD. Representative images are shown. The arrows indicate
the direction of migration. The upper black lines indicate the starting line and the lower black lines indicate the mean migration distance.
doi:10.1371/journal.pone.0002790.g009
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rearrangement of the cytoskeleton and the formation of pseudo-
podia and membrane ruffles. These changes increase breast cancer
cell invasion of the surrounding environment. PR signaling seems
to be ligand-specific, as in the presence of progesterone PR signals
to RhoA and ROCK-2 through the activation of Ga13, while in
the presence of MPA PR uses c-Src and PI3K. These observations
help to understand the role of progesterone receptor signaling in
breast cancer spread and could provide new molecular targets for
breast cancer treatment.
Materials and Methods
Cell cultures and treatments
T47-D breast cancer cells were incubated in phenol red-free
RPMI 1640 medium containing 10% fetal calf serum (FCS),
0.2 UI/mL insulin, L-glutamine and penicillin streptomycin under
a5 %C O 2 atmosphere at 37uC. Before experiments investigating
non-transcriptional effects, cells were kept in phenol red-free
DMEM containing no FBS for 8 hours. Whenever an inhibitor
was used, the compound was added 30 minutes before starting the
treatments. Progesterone, medroxyprogesterone acetate, 17b-
estradiol, hydrocortisone, pertussis toxin, Y-27632, PD98059,
wortmannin, actinomycin D and cycloheximide were from Sigma-
Aldrich (Saint-Louis, MO). 4-pregnen-3, 20-dione3-O-carboxy-
methyloxime: BSA (P-BSA) was from Steraloids (Steraloids
incorporation, Newport, RI). 4-amino-5-(4-chlorophenyl)-7-(t-bu-
tyl) pyrazolo (3,4-d) pyrimidine (PP2) was from Calbiochem (EMD
Biosciences, Germany). ORG 31710 was a kind gift of Dr. Lenus
Kloosterboer, from Organon Akzo Nobel (Oss, The Netherlands).
Immunoblottings
Cell lysates were separated by SDS-PAGE. Antibodies used
were: moesin (clone 38, Transduction Laboratories, Lexington,
KY), Thr
558-P-moesin (sc-12895, Santa Cruz Biotechnology,
Santa Cruz, CA), PR (sc-539, Santa Cruz), Tyr
204-P-ERK (sc-
7969, Santa Cruz), Ga13 protein (sc-410, Santa Cruz), ERK1/
ERK2 (444944, Calbiochem-Novabiochem Corporation, San
diego, CA), Thr
34-P-Akt (07-789, Upstate, Lake Placid, NY), Akt
(9272, Cell signalling technology, Danvers, MA). Primary and
secondary Abs were incubated with the membranes with standard
technique [51]. Immunodetection was accomplished using en-
hanced chemiluminescence. Chemiluminescence was acquired
with a quantitative digital imaging system (Quantity One, BioRad,
Hercules, CA) allowing to check for saturation. Overall emitted
photons were quantified for each band, particularly for loading
controls, which were homogeneously loaded.
Kinase assays
T47-D cells were harvested in 20 mM Tris-HCl, 10 mM
EDTA, 100 mM NaCl, 0.5% IGEPAL and 0.1 mg/mL PMSF.
Equal amounts of cell lysates were immunoprecipitated with
Rhotekin RBD agarose (14-383, upstate) vs. GTP-RhoA or an Ab
vs. ROCK-2 (C-20, Santa Cruz). The IPs were washed three times
with buffer containing 20 mM Tris-HCl, 10 mM EDTA,
150 mM NaCl, 0.1% IGEPAL and 0.1 mg/mL PMSF. For
Figure 10. Intracellular signaling steps involved in PR-enhanced T47-D cell invasion. (A) and (B) T47-D cells were treated with
progesterone or MPA (both 100 nM) for 24 h, in the presence or absence of the substances as previously indicated or of transfection with moesin
antisense phosphorotioate oligonucleotides (PON) (antisense - 2 mM) or sense PON (sense - 2 mM) for 48 h and cell invasion was assayed using
invasion chambers. Invading cells were counted in three different central fields of triplicate membranes. Invasion indexes and representative images
are shown. *=P,0.01 vs. control, **=P,0.05 vs P or MPA. The experiments were performed in triplicates. Invasion indexes and representative
images are shown.
doi:10.1371/journal.pone.0002790.g010
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kinase assay buffer (20 mM MOPS, 25 mM b-glycerophosphate,
5 mM EGTA, 1 mM DTT) and the samples were therefore
resuspended in this buffer. 5 mg of de-phosphorylated myelin basic
protein (Upstate) together with 500 mM ATP and 75 mM MgCl2
were added to each sample and the reaction was started at 30uC
for 20 min. The reaction was stopped on ice and by resuspending
the samples in Laemmli Buffer. The samples were separated with
SDS-PAGE and Western analysis was performed using antibodies
recognizing RhoA (sc-418, Santa Cruz) or Thr
98-P-myelin basic
protein (05-429, Upstate).
Cell immunofluorescence
T47-D breast cancer cells were grown on coverslips and
exposed to treatments. Cells were fixed with 4% paraformalde-
hyde for 30 min and permeabilized with 0.1% Triton X for 5 min.
Blocking was performed with 3% normal serum for 20 min. Cells
were incubated with antibodies against Ga13 or PR (sc-418, Santa
Cruz). After washing the nuclei were counterstained with 49-6-
diamidino-2-phenylindole (DAPI) (Sigma) and actin was stained
with Texas Red-phalloidin (Sigma). The coverslips were mounted
with Vectashield mounting medium (Vector Laboratories, Burlin-
game, CA). Immunofluorescence was visualized using an Olympus
BX41 microscope and recorded with a high-resolution DP70
Olympus digital camera. Pictures were photographed. Cell
membrane thickness and the gray level of extracellular area, cell
membrane as well as cytoplasm were quantitated using Leica
QWin image analysis and image processing software (Leica
Microsystems, Wetzlar, Germany).
Transfection experiments
On-TARGETplus SMARTpool siRNA reagents against hu-
man MAPK (NM-138957), ROCK-2 (NM-004850), Src (NM-
198291) and control siRNA (D-001810-01-05) were purchased
from Dharmacon (Thermo Fisher Scientific Inc, USA). T47-D
cells were transfected with siRNA using Lipofectamine (Invitrogen)
according to the protocol. Cells (40% confluent) were serum-
starved for 1 h followed by incubation with 100 nM target siRNA
or control siRNA for 6 h in serum-free media. The serum-
containing media was then added (10% serum final concentration)
for 42 h before experiments and/or functional assays were
conducted. Target protein silencing was assessed through protein
analysis up to 48 h after transfection.
Each plasmid (15 mg) was transfected into T47-D breast cancer
cells using the Lipofectamine (Invitrogen) according to the
manufacturer’s instructions. The transfected plasmids were as
follows: Ga13 Q226L, Ga13 Q226L/D294N, RhoA T19 and
RhoA G14V, p85a or dominant-negative p85a (Dp85a). These
constructs were obtained from the Guthrie cDNA Resource
Center (www.cdna.org). Plasmids for CMV human progesterone
receptor A (hPR-A, # 95) and B (hPR-A, # 90) were provided by
Dean P. Edwards (Baylor college of medicine, USA). All the inserts
were cloned in pcDNA3.1+. As control, parallel cells were
transfected with empty pcDNA3.1+ plasmid. Cells (60–70%
confluent) were treated 24 h after transfection, and cellular
extracts were prepared according to the experiments to be
performed.
Validated antisense phosphorotioate oligonucleotides (S-modi-
fied) (PONs) complementary to the 1–15 position of the human
moesin gene coding region were obtained from Dharmacon. The
sequence was 59-TACGGGTTTTGCTAG-39 for moesin anti-
sense PON. The complementary sense PON was used as control
(59-CTAGCAAAACCCGTA-39). Transfections were performed
on subconfluent T47-D cells. PONs were resuspended in serum-
free medium with Lipofectamine (Invitrogen) and added to the
culture medium every 12 h at the final concentration of 4 mM.
Every 24 h, cells were washed and fresh medium supplemented
with 4 mM PONs was added. Moesin silencing was assessed
through protein analysis up to 48 h after transfection.
G-actin /F-actin in vivo assay
G-actin/F-actin in vivo assay kit was purchased from Cytoskel-
eton Inc (# BK037, Denver, USA). This kit is used to determine
accurately the amount of filamentous actin (F-actin) content versus
free globular-actin (G-actin) content in a cell population. In brief,
confluent T47-D cells were harvested with 37uC warm lysis and F-
actin stabilization buffer (50 mM PIPES, 50 mM KCl, 5 mM
MgCl2, 5 mM EGTA, 5% glycerol, 0.1% Nonidet P40, 0.1%
Triton X-100, 0.1% Tween 20, 0.1% 2-mercapto-ethanol,
0.001% antifoam C, 1 mM ATP) after required treatments. Total
protein concentration was determined by standard method.
Positive and negative controls were set by adding F-actin
enhancing solution (phalloidin, 1 mM) or F-actin depolymerization
solution (10 mM cytochalasin-D) to the lysates, respectively. The
lysates were incubated at 37uC for 10 min, followed by a
centrifuge at 2000 rpm for 5 min to pellet and discard unbroken
cells. Supernatant were centrifuged at 10,0006g for 1 h at 37uC.
After that, supernatant and pellet were both collected. Pellets were
resuspended to the same volume as the supernatant using ice cold
distilled water plus F-actin depolymerization solution (10 mM
cytochalasin-D) and put on ice for 1 h to dissociate F-actin.
According to the protein concentration previously measured,
equivalent volumes of supernatant and dissolved pellet were
loaded to run Western blot and G-actin/F-actin ratio was
quantitiated using the quantitative digital imaging system.
Cell migration assays
Cell migration was assayed with razor scrape assays as
previously described [12]. Briefly, a razor blade was pressed
through the confluent T47-D breast cancer cell monolayer into the
plastic plate to mark the starting line. T47-D cells were swept away
on one side of that line. Cells were washed, and 2.0 mL of DMEM
containing steroid-deprived FBS and gelatin (1 mg/mL) were
added. Cytosine b-D-arabinofuranoside hydrochloride (Sigma)
(10 mM), a selective inhibitor of DNA synthesis which doesn’t
inhibit RNA synthesis was used 1 h before the test substance was
added. Migration was monitored for 48 hours. Every 12 h fresh
medium and treatment were replaced. Cells were digitally imaged
and migration distance was measured by using phase-contrast
microscopy.
Cell invasion assays
Cell invasion were assayed following the standard method by
using the BD BioCoatTM Growth Factor Reduced (GFR)
Matrigel
TM Invasion Chamber (BD Bioscience, USA). In brief,
after rehydrating the GFR Matrigel inserts, the test substance was
added to the wells. An equal number of Control Inserts (no GFR
Matrigel coating) were prepared as control. 0.5 mL of T47-D cell
suspension (2.5610
4 cells/mL) were added to the inside of the
inserts. The chambers were incubated for 24 h at 37uC, 5% CO2
atmosphere. After incubation, the non-invading cells were
removed from the upper surface of the membrane using cotton
tipped swabs. Then the cells on the lower surface of the membrane
were stained with Diff-Quick stain. The invading cells were
observed and photographed under the microscope at 1006
magnification. Cells were counted in the central field of triplicate
membranes. The invasion index was calculated as the % invasion
test cell/ % invasion control cell.
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All values are expressed as mean6SD. Statistical differences
between mean values were determined by ANOVA, followed by
the Fisher’s protected least significance difference (PLSD). All
differences were considered significant at P,0.05.
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